Clinical Trial Update: Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating safety, tolerability and immunogenicity of Pneumovax 23 in healthy adults in India has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infection | Phase 3 | Status: COMPLETED